Damora Therapeutics Opens Mutant-CALR Trial
Damora Therapeutics initiated CLARITY-101, a global Phase 1/1b trial of DMR-001 in adults with mutant-calreticulin-driven essential thrombocythemia or myelofibrosis. DMR-001 is an Fc-null monoclonal antibody designed to bind Type 1 and non-Type 1 mutant…
